| 主权项 |
1. A pharmaceutical composition comprising:
A Compound of Formula I or pharmaceutically acceptable salts thereof, wherein:
ring A is selected from: R1 is —CF3, —CN, or —C≡CCH2N(CH3)2;R2 is hydrogen, —CH3, —CF3, —OH, or —CH2OH;R3 is hydrogen, —CH3, —OCH3, or —CN; provided that both R2 and R3 are not simultaneously hydrogen; and one or both of the following: B. A Compound of Formula II or pharmaceutically acceptable salts thereof, wherein: T is —CH2—, —CH2CH2—, —CF2—, —C(CH3)2—, or —C(O)—; R1′ is H, C1-6 aliphatic, halo, CF3, CHF2, O(C1-6 aliphatic); and RD1 or RD2 is ZDR9 wherein:ZD is a bond, CONH, SO2NH, SO2N(C1-6 alkyl), CH2NHSO2, CH2N(CH3)SO2, CH2NHCO, COO, SO2, or CO; andR9 is H, C1-6 aliphatic, or aryl; and/or C. A Compound of Formula III or pharmaceutically acceptable salts thereof, wherein: R is H, OH, OCH3 or two R taken together form —OCH2O— or —OCF2O—; R4 is H or alkyl; R5 is H or F; R6 is H or CN; R7 is H, —CH2CH(OH)CH2OH, —CH2CH2N+(CH3)3, or —CH2CH2OH; R8 is H, OH, —CH2CH(OH)CH2OH, —CH2OH, or R7 and R8 taken together form a five membered ring. |
